title: Emerging drugs for bipolar disorder.
abstract: Bipolar disorder is a relatively common condition characterised by recurrent episodes of mania and depression, and associated with high levels of morbidity and mortality. Although there have been substantial advances in the pharmacotherapeutics of this condition over the last 10-15 years, the benefits have been predominantly in terms of tolerability and safety, with no new treatments being demonstrated to be more effective than lithium--the prototype mood stabiliser. This article reviews current and emerging medications for bipolar disorder. Most of the emerging treatments in pharmaceutical industry developmental programmes are new or modified anticonvulsants or atypical antipsychotics. A number of possible future directions and challenges for the field are discussed. The treatment of bipolar disorder is unlikely to advance substantially until the causative pathogenetic molecular processes are elucidated.
authors.affiliation: School of Psychiatry, University of New South Wales, Black Dog Institute, Prince of Wales Hospital, Randwick, Sydney, NSW 2031, Australia. phil.mitchell@unsw.edu.au
authors.forename: Philip B
authors.initials: PB
authors.lastname: Mitchell
authors.forename: Gin S
authors.initials: GS
authors.lastname: Malhi
mesh_terms: D001714:Bipolar Disorder / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans
chemical_list: D015507:Drugs, Investigational